BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 15505154)

  • 1. 1H MR spectroscopy in common dementias.
    Kantarci K; Petersen RC; Boeve BF; Knopman DS; Tang-Wai DF; O'Brien PC; Weigand SD; Edland SD; Smith GE; Ivnik RJ; Ferman TJ; Tangalos EG; Jack CR
    Neurology; 2004 Oct; 63(8):1393-8. PubMed ID: 15505154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-brain patterns of (1)H-magnetic resonance spectroscopy imaging in Alzheimer's disease and dementia with Lewy bodies.
    Su L; Blamire AM; Watson R; He J; Hayes L; O'Brien JT
    Transl Psychiatry; 2016 Aug; 6(8):e877. PubMed ID: 27576166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies.
    Graff-Radford J; Boeve BF; Murray ME; Ferman TJ; Tosakulwong N; Lesnick TG; Maroney-Smith M; Senjem ML; Gunter J; Smith GE; Knopman DS; Jack CR; Dickson DW; Petersen RC; Kantarci K
    Neurobiol Aging; 2014 Jun; 35(6):1483-90. PubMed ID: 24468473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging.
    MacKay S; Meyerhoff DJ; Constans JM; Norman D; Fein G; Weiner MW
    Arch Neurol; 1996 Feb; 53(2):167-74. PubMed ID: 8639067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia.
    Jones RS; Waldman AD
    Neurol Res; 2004 Jul; 26(5):488-95. PubMed ID: 15265265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study.
    Waldman AD; Rai GS
    Neuroradiology; 2003 Aug; 45(8):507-12. PubMed ID: 12879326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey.
    García Santos JM; Gavrila D; Antúnez C; Tormo MJ; Salmerón D; Carles R; Jiménez Veiga J; Parrilla G; Torres del Río S; Fortuna L; Navarro C
    Dement Geriatr Cogn Disord; 2008; 26(1):15-25. PubMed ID: 18566544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using proton magnetic resonance spectroscopy to identify mild cognitive impairment.
    Wang T; Xiao S; Li X; Ding B; Ling H; Chen K; Fang Y
    Int Psychogeriatr; 2012 Jan; 24(1):19-27. PubMed ID: 21676281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative proton magnetic resonance spectroscopy detects abnormalities in dorsolateral prefrontal cortex and motor cortex of patients with frontotemporal lobar degeneration.
    Chawla S; Wang S; Moore P; Woo JH; Elman L; McCluskey LF; Melhem ER; Grossman M; Poptani H
    J Neurol; 2010 Jan; 257(1):114-21. PubMed ID: 19688233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study.
    Huang W; Alexander GE; Chang L; Shetty HU; Krasuski JS; Rapoport SI; Schapiro MB
    Neurology; 2001 Aug; 57(4):626-32. PubMed ID: 11524470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of increased cerebral myo-inositol in the dementia of Down syndrome.
    Shonk T; Ross BD
    Magn Reson Med; 1995 Jun; 33(6):858-61. PubMed ID: 7651126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of SPM8 plus DARTEL (VSRAD) combined with magnetic resonance spectroscopy as adjunct techniques for screening and predicting dementia due to Alzheimer's disease in clinical practice.
    Waragai M; Hata S; Suzuki T; Ishii R; Fujii C; Tokuda T; Arai H; Ohrui T; Higuchi S; Yoshida M; Igarashi K; Moriya M; Iwai N; Uemura K
    J Alzheimers Dis; 2014; 41(4):1207-22. PubMed ID: 24787913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRS in mild cognitive impairment: early differentiation of dementia with Lewy bodies and Alzheimer's disease.
    Zhang B; Ferman TJ; Boeve BF; Smith GE; Maroney-Smith M; Spychalla AJ; Knopman DS; Jack CR; Petersen RC; Kantarci K
    J Neuroimaging; 2015; 25(2):269-274. PubMed ID: 25039916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
    Frederick BD; Lyoo IK; Satlin A; Ahn KH; Kim MJ; Yurgelun-Todd DA; Cohen BM; Renshaw PF
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1313-22. PubMed ID: 15588758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Alzheimer disease on fronto-parietal brain N-acetyl aspartate and myo-inositol using magnetic resonance spectroscopic imaging.
    Zhu X; Schuff N; Kornak J; Soher B; Yaffe K; Kramer JH; Ezekiel F; Miller BL; Jagust WJ; Weiner MW
    Alzheimer Dis Assoc Disord; 2006; 20(2):77-85. PubMed ID: 16772742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of 1H-MR spectroscopy and cerebrospinal fluid biomarkers in Alzheimer's disease: diverging behavior at three different brain regions.
    Bittner DM; Heinze HJ; Kaufmann J
    J Alzheimers Dis; 2013; 36(1):155-63. PubMed ID: 23579327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased N-Acetyl Aspartate/Myo-Inositol Ratio in the Posterior Cingulate Cortex Shown by Magnetic Resonance Spectroscopy May Be One of the Risk Markers of Preclinical Alzheimer's Disease: A 7-Year Follow-Up Study.
    Waragai M; Moriya M; Nojo T
    J Alzheimers Dis; 2017; 60(4):1411-1427. PubMed ID: 28968236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and Alzheimer disease.
    Wang Z; Zhao C; Yu L; Zhou W; Li K
    Acta Radiol; 2009 Apr; 50(3):312-9. PubMed ID: 19235582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy.
    Weiss U; Bacher R; Vonbank H; Kemmler G; Lingg A; Marksteiner J
    J Clin Psychiatry; 2003 Mar; 64(3):235-42. PubMed ID: 12716263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1H-proton magnetic resonance spectroscopy differentiates dementia with Lewy bodies from Alzheimer's disease.
    Zhong X; Shi H; Shen Z; Hou L; Luo X; Chen X; Liu S; Zhang Y; Zheng D; Tan Y; Huang G; Fang Y; Zhang H; Mu N; Chen J; Wu R; Ning Y
    J Alzheimers Dis; 2014; 40(4):953-66. PubMed ID: 24531156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.